Absci

Absci Debt Growth

The Year-over-Year Debt Growth of Absci (ABSI) as of Oct 16, 2026 is -34.17 %. In the previous year, Year-over-Year Debt Growth was -52.89 % — a change of -35.40% (higher).

Debt Growth

-34.17 %

YoY

-35.40%

Last updated:

Year-over-Year Debt Growth of Absci is 2025 -34.17 % . Year-over-Year Debt Growth of Absci was 2024 -52.89 % . It decreases by -35.40% higher compared to the previous year.

The Absci Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2020
116.28 USD
Jan 1, 2021
2.15 USD
Jan 1, 2022
47.37 USD
Jan 1, 2023
-38.32 USD
Jan 1, 2024
-52.89 USD
Jan 1, 2025
-34.17 USD
The Absci Debt Growth history
YEARDebt GrowthYoY
-34.17 %-35.40%
-52.89 %+38.02%
-38.32 %-180.90%
47.37 %+2,102.63%
2.15 %-98.15%
116.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Absci Stock analysis

What does Absci do? Absci Corp, trading under the ticker ABSI with ISIN US00091E1091, is a biotechnology company headquartered in Vancouver, Washington, operating within the Health Care sector. The company went public via an IPO on July 22, 2021. Absci employs 140 people. It leverages artificial intelligence and synthetic biology to explore and expand the therapeutic potential of proteins. The company utilizes a platform combining AI with scalable wet lab technologies to develop biologics for patients. Absci's approach involves identifying novel drug targets, discovering biotherapeutic candidates, and generating cell lines for manufacturing within a single integrated process. The firm applies generative AI to design drug candidates optimized for target affinity, safety, manufacturability, and other characteristics. Absci's technology includes SoluPro, a multiplex synthetic biology method that addresses limitations of high-throughput automation labs. The company supports its AI-driven designs with high-throughput functional validation capabilities in its wet lab. Absci's website is www.absci.com, providing information about its services and technology. The company focuses on creating biologic drug candidates for partners, using data generated from its processes to refine and improve its platform. Absci is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Absci stock

Year-over-Year Debt Growth of Absci is -34.17 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Absci since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Absci historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Absci

All Key Metrics — Absci